Vogt Frederick G 4

What Happened

• Frederick G. Vogt, Interim CEO & General Counsel (also a director) at Iovance Biotherapeutics, had 62,493 restricted stock units (RSUs) convert to common shares on March 5, 2026. The conversion was reported as an exercise/conversion (code M) at $0.00 per share. To satisfy mandatory tax withholding, 26,755 of those shares were withheld by the issuer (reported as disposition code F) at an implied value of $4.58 per share, totaling $122,538. After withholding, Vogt retained 35,738 shares.

Key Details

• Transaction date: 2026-03-05 (reported on Form 4 filed 2026-03-06).
• Vesting/conversion: 62,493 RSUs -> 62,493 common shares (code M, $0.00 exercise price).
• Tax withholding: 26,755 shares withheld (code F) at $4.58/share = $122,538; this was not an open-market sale.
• Shares remaining after withholding: 35,738 (per footnote describing remaining common stock).
• Footnotes: RSUs vesting on the date; each RSU equals one share; remaining RSUs will vest in equal quarterly installments; the reported number reflects the remainder of RSUs from the March 5, 2025 grant.
• Filing timeliness: Report covers 2026-03-05 and was filed 2026-03-06 (appears timely).

Context

• This was a routine vesting of RSUs and withholding to cover tax obligations (a non‑market disposition). There was no open‑market sale of shares and no cash purchase — the underlying RSUs simply converted to shares and the company retained a portion to satisfy taxes. Such award vestings are standard compensation events and do not by themselves indicate a change in insider confidence.